About 22nd Century Group (NYSE:XXII)
22nd Century Group, Inc. is a plant biotechnology company. The Company is focused on technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. It is engaged in various activities, including research and development of less harmful or modified risk tobacco products and tobacco plant varieties; development of X-22, a smoking cessation aid consisting of very low nicotine (VLN) cigarettes; manufacture, marketing and distribution of its RED SUN and MAGIC cigarettes; production of SPECTRUM research cigarettes for the National Institute on Drug Abuse (NIDA); contract manufacturing of third-party branded tobacco products, and research and development of plant varieties of hemp/cannabis, such as plants with low to no amounts of delta-9-tetrahydrocannabinol (THC), plants with high levels of cannabidiol (CBD), and other non-THC cannabinoids.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NYSE:XXII
- CUSIP: N/A
- Web: N/A
- Market Cap: $126.34 million
- Outstanding Shares: 90,895,000
- 50 Day Moving Avg: $1.35
- 200 Day Moving Avg: $1.10
- 52 Week Range: $0.77 - $1.71
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -13.90
- P/E Growth: 0.00
- Annual Revenue: $11.49 million
- Price / Sales: 11.00
- Book Value: $0.24 per share
- Price / Book: 5.79
- Average Volume: 941,830 shs.
- Short Ratio: 4.35
Frequently Asked Questions for 22nd Century Group (NYSE:XXII)
What is 22nd Century Group's stock symbol?
22nd Century Group trades on the New York Stock Exchange (NYSE) under the ticker symbol "XXII."
How were 22nd Century Group's earnings last quarter?
22nd Century Group Inc (NYSE:XXII) posted its quarterly earnings results on Tuesday, May, 10th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.01. The business earned $3.02 million during the quarter. View 22nd Century Group's Earnings History.
Where is 22nd Century Group's stock going? Where will 22nd Century Group's stock price be in 2017?
1 brokers have issued 1-year price objectives for 22nd Century Group's stock. Their predictions range from $3.50 to $3.50. On average, they anticipate 22nd Century Group's share price to reach $3.50 in the next twelve months. View Analyst Ratings for 22nd Century Group.
What are analysts saying about 22nd Century Group stock?
Here are some recent quotes from research analysts about 22nd Century Group stock:
- 1. According to Zacks Investment Research, "22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York. " (5/17/2017)
- 2. Chardan Capital analysts commented, "We expect 22nd Century to report Q4 results this week. Our revenue estimate for the quarter is $3.1 million, equivalent to Q3 results. For the full year this results in revenue of $12 million. We expect the company on its earnings call to focus on recent communications with the FDA regarding its PMTA (Premarket Tobacco Product Applications), the MRTP (Modified Risk Tobacco Product) applications and a path forward for X-22. Earlier this month the FDA granted a guidance meeting to discuss X-22 and the ways 22nd Century could attempt to win approval for X-22 as a prescription-based aid for smoking cessation. The company has also received written feedback on the MRTP application for Brand A, the company's very low nicotine (VLN) cigarette. As we progress through the year we expect additional milestones to be reached on 22nd Century's attempt to use its proprietary technology to create VLN products for the smoking cessation market." (3/7/2017)
Are investors shorting 22nd Century Group?
22nd Century Group saw a drop in short interest in April. As of April 28th, there was short interest totalling 4,414,704 shares, a drop of 7.3% from the April 13th total of 4,763,832 shares. Based on an average daily volume of 1,048,744 shares, the days-to-cover ratio is presently 4.2 days. Approximately 6.0% of the shares of the company are sold short.
Who are some of 22nd Century Group's key competitors?
Some companies that are related to 22nd Century Group include Curis (CRIS), Anavex Life Sciences Corp. (AVXL), Abeona Therapeutics (ABEO), Cascadian Therapeutics (CASC), Aratana Therapeutics (PETX), Codexis (CDXS), Chimerix (CMRX), Osiris Therapeutics (OSIR), Cempra (CEMP), Arbutus Biopharma Corp (ABUS), Madrigal Pharmaceuticals (MDGL), Immune Design Corp (IMDZ), Fortress Biotech (FBIO), Corium International (CORI), Stemline Therapeutics (STML), Enzymotec Ltd (ENZY), RedHill Biopharma Ltd - (RDHL) and Novelion Therapeutics (NVLN).
Who owns 22nd Century Group stock?
22nd Century Group's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.71%), Geode Capital Management LLC (0.49%) and National Asset Management Inc. (0.19%). Company insiders that own 22nd Century Group stock include John T Brodfuehrer, Joseph Pandolfino and Michael Robert Moynihan. View Institutional Ownership Trends for 22nd Century Group.
Who bought 22nd Century Group stock? Who is buying 22nd Century Group stock?
How do I buy 22nd Century Group stock?
Shares of 22nd Century Group can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of 22nd Century Group stock cost?
One share of 22nd Century Group stock can currently be purchased for approximately $1.39.
Consensus Ratings for 22nd Century Group (NYSE:XXII) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$3.50 (151.80% upside)|
Analysts' Ratings History for 22nd Century Group (NYSE:XXII)
(Data available from 5/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|3/7/2017||Chardan Capital||Reiterated Rating||Buy||$3.50||N/A|
Earnings History for 22nd Century Group (NYSE:XXII)Earnings History by Quarter for 22nd Century Group (NYSE:XXII)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/4/2015||Q215||($0.02)||($0.02)||$1.30 million||$2.31 million||View||N/A|
Earnings Estimates for 22nd Century Group (NYSE:XXII)
Current Year EPS Consensus Estimate: $-0.10 EPS
Next Year EPS Consensus Estimate: $-0.10 EPS
Dividend History for 22nd Century Group (NYSE:XXII)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for 22nd Century Group (NYSE:XXII)Insider Trades by Quarter for 22nd Century Group (NYSE:XXII)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/31/2016||Michael Robert Moynihan||VP||Sell||100,000||$1.28||$128,000.00|| |
|3/29/2016||John T Brodfuehrer||CFO||Buy||12,500||$0.77||$9,625.00|| |
|11/3/2015||Michael Robert Moynihan||VP||Sell||50,000||$1.40||$70,000.00|| |
|6/30/2015||Joseph Pandolfino||Director||Sell||91,178||$0.95||$86,619.10|| |
|12/31/2014||Joseph Pandolfino||Director||Sell||105,124||$1.65||$173,454.60|| |
|12/26/2014||Joseph Pandolfino||Director||Sell||41,722||$1.54||$64,251.88|| |
|12/22/2014||Joseph Pandolfino||Director||Sell||52,683||$1.60||$84,292.80|| |
|12/17/2014||Joseph Pandolfino||Director||Sell||75,768||$1.62||$122,744.16|| |
|12/11/2014||Joseph Pandolfino||Director||Sell||67,836||$1.65||$111,929.40|| |
|5/9/2014||Richard M Sanders||Director||Buy||20,000||$2.23||$44,600.00|| |
|4/23/2014||Michael Robert Moynihan||VP||Sell||100,000||$2.44||$244,000.00|| |
|3/12/2014||Joseph Pandolfino||CEO||Sell||95,000||$5.73||$544,350.00|| |
|12/10/2013||Clearwater Partners, Llc||Major Shareholder||Sell||10,000||$1.55||$15,500.00|| |
|12/3/2013||Clearwater Partners, Llc||Major Shareholder||Sell||10,000||$1.35||$13,500.00|| |
|11/19/2013||Clearwater Partners, Llc||Major Shareholder||Sell||30,074||$1.09||$32,780.66|| |
|11/13/2013||Clearwater Partners, Llc||Major Shareholder||Sell||11,826||$0.98||$11,589.48|| |
|11/11/2013||Clearwater Partners, Llc||Major Shareholder||Sell||7,100||$1.03||$7,313.00|| |
|11/7/2013||Clearwater Partners, Llc||Major Shareholder||Sell||9,000||$1.15||$10,350.00|| |
Headline Trends for 22nd Century Group (NYSE:XXII)
Latest Headlines for 22nd Century Group (NYSE:XXII)
22nd Century Group (XXII) Chart for Monday, May, 22, 2017